[[1] Abdo CHN, Jr WMO, Scanavino MT, Martins FG. Erectile dysfunction: results of the Brazilian Sexual Life Study. Rev. Assoc. Med. Bras. 2006;52(6):424-429.]Search in Google Scholar
[[2] Afif-Abdo J. Diagnóstico e Tratamento da disfunção erétil. Med. Sex. 2007;12(4):192-195.]Search in Google Scholar
[[3] Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. Vasc. Health Risk. Manag. 2006;2(4):411-422.]Search in Google Scholar
[[4] Council of Europe. European Pharmacopoeia 8.0. Germany: Druckerei C. H. Beck; 2015.]Search in Google Scholar
[[5] Dodgen AL, Hill KD. Safety and tolerability considerations in the use of sildenafil for children with pulmonary arterial hypertension. Drug Health Patient Saf. 2015;15(7): 175-183.]Search in Google Scholar
[[6] Ferreira AO, Polonini HC, Silva SL, Patrício FB, Brandão MAF, Raposo NR. Feasibility of amlodipine besylate, chloroquine phosphate, dapsone, phenytoin, pyridoxine hydrochloride, sulfadiazine, sulfasalazine, tetracycline hydrochloride, trimethoprim and zonisamide in SyrSpend® SF PH4 oral suspensions. J. Pharm. Biomed. Anal. 2016;118:105-112.]Search in Google Scholar
[[7] Geiger CM, Voudrie MA, Sorenson, B. Stability of ursodiol in SyrSpend SF Cherry Flavored. Int. J. Pharm. Compd. 2012a;16:510-512.]Search in Google Scholar
[[8] Geiger CM, Sorenson B, Whaley PA. Stability of captopril in SyrSpend SF. Int. J. Pharm. Compd. 2013a;17:336-338.]Search in Google Scholar
[[9] Geiger CM, Sorenson B, Whaley PA. Stability of midazolam in SyrSpend SF and SyrSpend SF Cherry. Int. J. Pharm. Compd. 2013b;17:344-346.]Search in Google Scholar
[[10] Geiger CM, Voudrie MA, Sorenson B. Stability of propranolol hydrochloride in SyrSpend SF. Int. J. Pharm. Compd. 2012b;16:513-515.]Search in Google Scholar
[[11] Geiger CM, Sorenson B, Whaley P. Stability assessment of 10 Active Pharmaceutical Ingredients compounded in SyrSpend SF. Int. J. Pharm. Compd. 2015;19:427-435.]Search in Google Scholar
[[12] Gershanik J, Boecler B, Ensley H. The gasping syndrome and benzyl alcohol poisoning. New Engl. J. Med. 1982;307:1384-1388.]Search in Google Scholar
[[13] Huddleston AJ, Knoderer CA, Morris JL. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr. Cardiol. 2009;30(7): 871-882.]Search in Google Scholar
[[14] Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, openlabel, pilot study. Circulation 2005;111(24):3274-3280.10.1161/CIRCULATIONAHA.104.47337115956137]Search in Google Scholar
[[15] ICH - International Conference On Harmonisation Of Technical Requirements For Registration Of Pharmaceuticals For Human Use. Validation of Analytical Procedures: text and methodology Q2(R1); 2005.]Search in Google Scholar
[[16] Jooste N. Extemporaneous preparation in a resource-limited setting: sildenafil citrate suspension. S. Afr. Pharm. J. 2011;78(8): 49-50.]Search in Google Scholar
[[17] Keller RL, Hmrick, SE, Kitterman JA, Fineman JR, Hawgood S. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr. Crit. Care Med. 2004;5(2):184-187.]Search in Google Scholar
[[18] Kothari SS, Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. 2002;54(4): 404-409.]Search in Google Scholar
[[19] Ladha F, Bonnet S, Eaton F, Hashimoto K, Korbutt G, Thébaud T. Sildenafil improves alveolar growth and pulmonary hypertension in hyperoxia-induced lung injury. Am. J. Respir. Crit. Care Med. 2005;172(6):750-756.]Search in Google Scholar
[[20] Lau ETL, Steadman KJ, Mak M, Cichero JAY, Nissen LM. Prevalence of swallowing difficulties and medication modification in customers of community pharmacists. J. Pharm. Pract. Res. 2015;45:18-23.]Search in Google Scholar
[[21] Leibovitch L, Matok I, Paret G. Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension. Drugs 2007;67(1):57-73.10.2165/00003495-200767010-0000517209664]Search in Google Scholar
[[22] Martínez EG, De Lrosa II, Navero JLP, Mateo IT, Montes JFE, Conde JC. Sildenafil in the treatment of pulmonary hypertension. An. Pediatr. 2003;59(1):110-113.]Search in Google Scholar
[[23] Montorsi F, Adaikan G, Becher E et al. Summary of the Recommendations on Sexual Dysfunctions in Men. J. Sex. Med. 2010; 7:3572-3588.]Search in Google Scholar
[[24] Nahata MC, Morosco RS, Brady MT. Extemporaneous sildenafil citrate oral suspensions for the treatment of pulmonary hypertension in children. Am. J. Health Syst. Pharm. 2006;63(3):254-257.]Search in Google Scholar
[[25] Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am. J. Respir. Crit. Care Med. 2006;174(9):1042-1047.]Search in Google Scholar
[[26] NIH Consensus Conference. Impotence. J. Am. Med. Assoc. 1993;270(1):83-90.10.1001/jama.270.1.83]Search in Google Scholar
[[27] Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MAF. Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions. Int. J. Pharm. Compd. 2016a;20(2):167.]Search in Google Scholar
[[28] Polonini HC, Silva SL, Cunha CN, Brandão MAF, Ferreira AO. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend® SF PH4 oral suspensions. Die Pharmazie 2015;71(4):185-191.]Search in Google Scholar
[[29] Polonini HC, Loures S, Araujo EP, Brandão MAF, Ferreira AO. Compatibility of allopurinol, amitriptyline HCl, carbamazepine, domperidone, isoniazid, ketoconazole, Lisinopril, naproxen, paracetamol (acetaminophen) and sertraline HCl in SyrSpend SF PH4 oral suspensions. Int. J. Pharm. Compd. 2016b. In press.]Search in Google Scholar
[[30] Polonini HC, Silva SL, de Almeida TR, Brandão MAF, Ferreira AO. Compatibility of caffeine, carvedilol, clomipramine hydrochloride, folic acid, hydrochlorothiazide, loperamide hydrochloride, methotrexate, nadolol, naltrexone hydrochloride and pentoxifylline in SyrSpend SF PH4 oral suspensions. Eur. J. Hosp. Pharm. 2016c. In press.10.1136/ejhpharm-2016-000903645146531156882]Search in Google Scholar
[[31] Porst H, Hell-Momeni K, Büttner H. Chronic PDE-5 inhibition in patients with erectile dysfunction -- a treatment approach using tadalafil once-daily. Expert Op. Pharmacother. 2012;13(10):1481-1494.]Search in Google Scholar
[[32] Provenza N, Calpena AC, Mallandrich M, Halbaut L, Clares B. Design and physicochemical stability studies of paediatric oral formulations of sildenafil. Int. J. Pharm. 2014;460(1):234-239.]Search in Google Scholar
[[33] Roque F, Rama AC, Sousa JJ, Pina ME. Development and stability assessment of liquid paediatric formulations containing sildenafil citrate. Braz. J. Pharm. Sci. 2013;49(2):381-388.]Search in Google Scholar
[[34] Schirm E, Tobi H, de Vries TW, Choonara I, De Jong-van den Berg LTW. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003;92:1486-1489.10.1111/j.1651-2227.2003.tb00837.x]Search in Google Scholar
[[35] Sorenson B, Whaley P. Stability of rifampin in SyrSpend SF. Int. J. Pharm. Compd. 2013;17:162-164.]Search in Google Scholar
[[36] Sorenson B, Voudrie MA, Gehrig D. Stability of gabapentin in SyrSpend SF. Int. J. Pharm. Compd. 2012;16:347-349.]Search in Google Scholar
[[37] Toledo ACT. Efeito da tadalafila na prevenção de alterações do corpo cavernoso após lesão vasculho-nervosa do feixe periprestático. Estudo experimental em ratos. PhD Thesis, Universidade Estadual de São Paulo: São Paulo, 2013.]Search in Google Scholar
[[38] Tissot C, Beghetti M. Advances in therapies for pediatric pulmonary arterial hypertension. Expert Rev. Respir. Med. 2009;3(3):265-282.]Search in Google Scholar
[[39] Voudrie MA, Allen DB. Stability of oseltamivir phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution). Int. J. Pharm. Compd. 2010;14:82-85.]Search in Google Scholar
[[40] Voudrie MA, Alexander B, Allen DB. Stability of verapamil hydrochloride compared to sorbitol containing syrup and suspending vehicles. Int. J. Pharm. Compd. 2011;15:255-258.]Search in Google Scholar
[[41] Vu NT, Aloumanis V, Ben M. Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System. Int. J. Pharm. Compd. 2008;12:558-564.]Search in Google Scholar
[[42] Whaley PA, Voudrie MA, Sorenson B. Stability of omeprazole in SyrSpend SF Alka (Reconstituted). Int. J. Pharm. Compd. 2012a;16:164-166.]Search in Google Scholar
[[43] Whaley PA, Voudrie MA, Sorenson B. Stability of vancomycin in SyrSpend SF. Int. J. Pharm. Compd. 2012b;16:167-169.]Search in Google Scholar
